Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.53), $0.16 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.26 million versus the consensus estimate of $5.34 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.